Andrew Roberts AM is Cancer Theme co-Leader at the Walter & Eliza Hall Institute of Medical Research (WEHI), a clinical haematologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre and the Metcalf Chair of Leukaemia Research at the University of Melbourne. A Past President of the Haematology Society of Australia and New Zealand (HSANZ; 2005 – 2007) and past Chair of the board of Cancer Council Victoria, he is currently a Director of the Australasian Leukaemia and Lymphoma Group and the Victorian Comprehensive Cancer Centre, and chairs the Life Saving Drug Program Expert Panel for the Australian Department of Health. He served on the Pharmaceutical Benefits Advisory Committee (PBAC) from 2007 – 2018 and is a member of the Reference Committee for the Health Technology Assessment Policy and Process Review currently being conducted for the Australian government. His laboratory and clinical research pioneered the way for venetoclax, the first in a new class of targeted anti-cancer drug, to become a routine treatment for selected leukaemias. For this work, he and colleagues have received multiple awards, including the 2018 Victoria Prize for Science and Innovation, the 2019 Prime Ministers Prize for Innovation and the 2020 Ramaciotti Medal for Excellence in Biomedical Research. Andrew was the first non-North American to serve as Scientific Co-Chair for the American Society of Hematology (ASH) Annual Meeting in 2015, and delivered the Ham-Wasserman Lecture at ASH in 2020. He is committed to advancing haematology internationally, serving as Deputy Editor of Blood since 2019, and to inspiring the next generation of haematology researchers and haematologists. Like Andrew, four of his PhD students have received the Albert J. Baikie Memorial Medal of the HSANZ, and three have won Premier’s Awards for Research.